Drug intelligence / Profile preview

Naloxone + Naltrexone

Development stage
Phase 1
Modality
Small Molecules
Administration
Intranasal
01

Overview

Naloxone + naltrexone is a combination of two opioid receptor antagonists, both of which act primarily at the μ-opioid receptor. Naloxone is used for the rapid reversal of opioid overdose by displacing opioids from their receptors and reversing life-threatening central nervous system and respiratory depression. It has a short half-life, often necessitating repeated dosing in cases of long-lasting opioids. Naltrexone is also a pure opioid antagonist with high affinity for μ-opioid receptors and some activity at κ and δ receptors; it blocks the effects of endogenous and exogenous opioids, reducing euphoria, cravings, and other subjective effects associated with opioid or alcohol use. When combined, these agents may extend the window for effective intervention after an overdose by providing both immediate (naloxone) and sustained (naltrexone) antagonism[1][2][3][5][6]. This combination has been studied in phase 1 trials to assess pharmacokinetics when administered intranasally[1].

Brand names
Evzio
02

Targets

DOR (Opioid Receptor Delta 1)FLNA (Filamin A)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on Naloxone + Naltrexone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Naloxone + Naltrexone.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call